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Gabapentin (GBP), a GABA analog that may also affect glutamate (Glu) production, can 
normalize GABA and Glu tone during early abstinence from alcohol, effectively treating 
withdrawal symptoms and facilitating recovery. Using in vivo magnetic resonance spec-
troscopy, we tested the degree to which daily GBP alters regional brain GABA and Glu 
levels in short-term abstinent alcohol-dependent individuals. Regional metabolite levels 
were compared between 13 recently abstinent alcohol-dependent individuals who had 
received daily GBP for at least 1 week (GBP+) and 25 matched alcohol-dependent indi-
viduals who had not received GBP (GBP−). Magnetic resonance spectra from up to five 
different brain regions were analyzed to yield absolute GABA and Glu concentrations. 
GABA and Glu concentrations in the parieto-occipital cortex were not different between 
GBP− and GBP+. Glu levels in anterior cingulate cortex, dorsolateral prefrontal cortex, 
and basal ganglia did not differ between GBP− and GBP+. However, in a subgroup of 
individuals matched on age, sex, and abstinence duration, GBP+ had markedly lower 
Glu in the frontal white matter (WM) than GBP−, comparable to concentrations found 
in light/non-drinking controls. Furthermore, lower frontal WM Glu in GBP+ correlated 
with a higher daily GBP dose. Daily GBP treatment at an average of 1,600 mg/day for 
at least 1 week was not associated with altered cortical GABA and Glu concentrations 
during short-term abstinence from alcohol, but with lower Glu in frontal WM. GBP for 
the treatment of alcohol dependence may work through reducing Glu in WM rather than 
increasing cortical GABA.
Keywords: gabapentin, alcohol use disorders, magnetic resonance spectroscopy, gaBa, glutamate, alcohol 
dependence, abstinence or withdrawal
inTrODUcTiOn
Orally administered gabapentin (GBP), a GABA analog and anticonvulsant that is easily absorbed 
and crosses the blood–brain barrier, has shown promise in treating seizures and neuropathic pain. It 
is currently approved to treat seizure disorders by decreasing seizure activity presumably via increas-
ing GABAergic tone and counter-balancing glutamatergic excitability (1). Monotherapy with GBP 
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is also used to manage alcohol withdrawal and dependence in 
recovering alcohol-dependent individuals [for review see Leung 
et al. (2)]; it has been shown to reduce alcohol craving and use 
as well as improve sleep, anxiety, and mood disturbances com-
monly present in early abstinence. Thus, GBP facilitates recovery 
in alcohol-dependent individuals with little to no risk for abuse 
potential and liver damage, all with good tolerability and safety 
profile [e.g., Ref. (3, 4)]. Mechanistically, GBP is thought to nor-
malize GABAergic tone via stimulating GABA synthesis and to 
affect glutamate (Glu) production in both neurons and glia (3, 5, 
6), thereby affecting the excitability of postsynaptic membranes.
In vivo proton magnetic resonance spectroscopy (1H MRS) 
can quantify both GABA and Glu concentrations in the brain. 
When given orally to healthy human volunteers, a single dose of 
17 mg/kg (7) or 900 mg of GBP (8) moderately increased MRS-
detected GABA levels in the visual cortex within a few hours, while 
leaving occipital cortical Glu levels unchanged (8); the lower the 
individual’s basal occipital GABA level, the greater the measured 
GABA increase to the fixed GBP dose. By contrast, single doses of 
150 or 300 mg of GBP did not change MRS-detectable GABA or 
Glu levels in the prefrontal or occipital cortices of healthy controls 
(9). In epileptic patients, 1H MRS demonstrated dose-dependent 
increases of initially low occipital cortical GABA levels after an 
initial dose and—to a lesser degree—after daily treatment with 
GBP (10–12). As with acute GBP administration to healthy con-
trols (8), epilepsy patients with the greatest GABA increases had 
the lowest pretreatment GABA levels. Furthermore, the epilepsy 
patients who demonstrated the best seizure control with GBP 
administration had above normal brain GABA concentrations. 
Glu levels were not assessed in these epilepsy studies.
For many years, MRS has been employed to measure GABA, 
Glu, and other metabolites throughout the brain of alcohol-
dependent individuals in outpatient treatment (ALC) who are not 
in acute withdrawal [for review see Meyerhoff (13)]. We observed 
that cortical GABA levels measured at approximately 1 week and 
1 month of abstinence from alcohol did not differ significantly 
from those in non/light-drinking controls (CON) (14–16). We 
also found that levels of cortical Glu and N-acetylaspartate (NAA, 
a biomarker of neuronal viability) were significantly lower in 
1-week-abstinent ALC than CON, suggesting neuronal injury 
and glutamatergic dysfunction reflected in imbalances of the 
metabolic Glu pool (14). Cortical GABA levels did not change 
in these ALC individuals between 1 and 5 weeks of abstinence 
from alcohol, whereas cortical Glu and NAA levels normalized 
over the same abstinence interval (14). During acute withdrawal, 
i.e., within a few days of sobriety, MRS-derived cortical Glu levels 
were elevated (17); however, we are not aware of any MRS studies 
that measured GABA levels during this time period. In frontal 
white matter (WM) and basal ganglia, our studies indicated lower 
NAA and myo-Inositol (mI, an astrocyte marker) in 4-week-
abstinent ALC (18, 19) and additional strong trends to lower Glu 
and creatine-containing metabolites (Cr, including creatine and 
phosphocreatine, a high-energy metabolite) in basal ganglia (19); 
we did not measure GABA in these non-cortical brain regions. 
Taken together, these studies in short-term abstinent ALC sug-
gest neuronal, glutamatergic and astrocytic abnormalities in 
fronto-striatal brain regions. Furthermore, cigarette smoking was 
shown associated with exacerbated reductions of regional NAA, 
Cr, and choline-containing metabolites (Cho) in ALC (20–22), 
with reduced dorsolateral prefrontal Glu concentration in non-
alcoholic controls (23), and with NAA concentration deficits in 
the left hippocampus but not the anterior cingulate cortex (ACC) 
of smoking vs. non-smoking controls (24).
None of the ALC patients we previously studied (described 
above) had received GBP during their outpatient treatment, 
which typically consisted of stabilization/early recovery treat-
ment for up to 30 days with psychosocial and cognitive behavioral 
programs attended 3–5 days per week. More recently, however, 
our referring treatment centers started managing their patients 
with GBP during early alcohol abstinence. This raised the ques-
tion whether GABA, Glu, or the other commonly measured MRS 
metabolite levels in the cortex of ALC treated with daily GBP 
during outpatient treatment differed from the corresponding 
metabolite levels in ALC we previously investigated that were 
not treated with GBP. Therefore, we decided to formally compare 
these two recovering ALC groups on their brain metabolite levels 
in the various brain regions we have been typically examining in 
our addiction MRS research. We hypothesized higher GABA and 
similar Glu levels in cortical brain regions of patients chronically 
treated with GBP compared to those not treated with GBP. To 
further explore GBP’s potential tissue type-specific metabolic 
response and to help illuminate its mechanism of action, we 
also compared metabolite concentrations from subcortical brain 
regions and frontal WM.
MaTerials anD MeThODs
Participants
Thirty-eight ALC (including eight females) between the ages 
of 25 and 60  years were referred by the VA Medical Center 
Substance Abuse Day Hospital and the Kaiser Permanente 
Chemical Dependence Recovery Program in San Francisco. In 
this naturalistic study design, 13 of these ALC had received daily 
oral GBP for at least 1 week before study (GBP+), whereas 25 
ALC had not received GBP (GBP−) from their treatment pro-
vider at any time before study. The duration of GBP treatment 
before study and the daily dose were estimated from information 
obtained from treatment providers and corroborated by patient 
self-report. Given the nature of the data obtained and the fact that 
this was not a prospective treatment trial, only the daily dose data 
allowed some quantitative analyses; the GBP duration data were 
sufficiently incomplete for most patients to allow computing reli-
able quantitative estimates beyond the statement that all patients 
received GBP for at least 1 full week before study. Sixteen CON 
similar in age (48.7 ± 12.3 years) to our ALC group were recruited 
from the local community and studied contemporaneously with 
the ALC participants.
All study participants provided written informed consent 
prior to study per the Declaration of Helsinki and underwent 
procedures approved by the Institutional Review Board of the 
University of California San Francisco and the San Francisco VA 
Medical Center. Primary inclusion criteria for ALC participants 
were fluency in English, DSM-IV diagnosis of alcohol dependence 
TaBle 1 | Demographic, clinical, and neuropsychological group characteristics.
Measure gBP− gBP+
N (including females) 25 (6) 13 (2)
Age (years) 47.4 ± 9.1 43.8 ± 11.5
Duration of abstinence (days) 19.3 ± 11.3 15.3 ± 10.4
AMNART 112 ± 9 117 ± 8
Beck Depression Inventory 13.0 ± 8.5 14.4 ± 8.4
Anxiety Inventory (State) 39.8 ± 13.7 33.4 ± 7.5
Anxiety Inventory (Trait) 45.9 ± 10.5 44.1 ± 14.5
Barratt Impulsivity Scale (total score) 64.6 ± 10.9 68.3 ± 10.6
Global cognition (Z-score) −0.12 ± 0.54 −0.04 ± 0.74
Onset age of heavy drinking (years) 26.5 ± 9.6 26.0 ± 10.4
Duration of heavy drinking (months) 210 ± 129 191 ± 134
Drinks per month over lifetime 187 ± 130 177 ± 122
Drinks per month year before study 319 ± 230 258 ± 171
Duration of smoking (years) 23.4 ± 13.6 21.0 ± 11.1
Cigarette pack years 15.4 ± 13.3 9.3 ± 10.9
Fagerstrom total score* 3.9 ± 1.6 (n = 17) 2.6 ± 1.1 (n = 7)
Mean ± SD. Only the Fagerstrom total score differed significantly between the smokers 
of the two groups (p = 0.05).
*p = 0.05.
AMNART, American National Adult Reading Test; GBP, Gabapentin.
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or abuse at the time of enrollment, consumption of >150 standard 
alcohol-containing drinks (i.e., 13.6 g of ethanol/drink) per month 
for at least 8 years prior to enrollment for men, or consumption 
of >80 drinks/month for at least 6 years prior to enrollment for 
women. Exclusion criteria for ALC participants were history of 
the following: dependence on any substance other than alcohol or 
nicotine in the 5 years prior to enrollment, any intravenous drug 
use in the 5 years prior to study, current opioid agonist therapy, 
intrinsic cerebral masses or vascular malformations, HIV/AIDS, 
cerebrovascular accident, myocardial infarction, uncontrolled 
chronic hypertension, type-1 diabetes or insulin dependent con-
ditions, moderate or severe COPD, non-alcohol related seizures, 
significant exposure to known neurotoxins, demyelinating and 
neurodegenerative diseases, documented Wernicke–Korsakoff 
syndrome, alcohol-induced persisting dementia, any penetrating 
head trauma, and closed head injury with loss of consciousness 
>10 min. Exclusion criteria also included history of schizophrenia- 
spectrum and bipolar disorders, PTSD, obsessive-compulsive 
disorder, and panic disorder. Hepatitis C, type-2 diabetes, 
hypertension, and unipolar mood disorder (major depression 
and/or substance-induced mood disorder) were permitted in the 
ALC cohort given their high prevalence in alcohol use disorders 
(AUDs) (25, 26). For ALC, inclusion/exclusion criteria were veri-
fied via electronic medical records, when available.
The ALC participants were involved in outpatient treatment 
at the time of assessment and none tested positive for alcohol 
or illicit substances (cannabinoids, cocaine, amphetamines, 
opioids, or PCP) before any of the assessments. Participants 
could be scanned only after their Clinical Institute Withdrawal 
Assessment for Alcohol Revised (CIWA-Ar) scores were below 10 
(mild alcohol withdrawal is defined by a CIWA-Ar score less than 
or equal to 15). GBP− and GBP+ groups had a similar average 
duration of abstinence when studied. All CON participants were 
fluent in English, had no history of any DSM-IV Axis I disorder 
or biomedical condition that may have adversely affected their 
neurobiology, and they had not endorsed averaging >50 standard 
alcohol-containing drinks during any month over lifetime.
clinical and neuropsychological 
assessments
All ALC participants completed the Structured Clinical Interview 
for DSM-IV Axis I Disorders, Version 2.0 and CON were admin-
istered the accompanying screening module. Semi-structured 
interviews for lifetime alcohol consumption [Lifetime Drinking 
History (LDH)] (27, 28) and substance use (in-house question-
naire assessing substance type and quantity and frequency of use) 
(29) were administered to all participants. From the LDH, average 
number of alcoholic drinks per month over 1 year prior to enroll-
ment, average number of drinks per month over lifetime, dura-
tion of heavy drinking (here operationalized as drinking >100 
drinks per month in males, >80 drinks per month in females) 
were calculated. Premorbid verbal intelligence was estimated 
with the American National Adult Reading Test. Participants 
also completed standardized questionnaires assessing depres-
sive (Beck Depression Inventory) (30) and anxiety symptoms 
(State-Trait Anxiety Inventory) (31), self-reported impulsivity 
(Barratt Impulsivity Scale) (32), and nicotine dependence via the 
Fagerstrom Tolerance Test for Nicotine Dependence (33). Table 1 
shows demographics, behavioral measures, alcohol, and cigarette 
consumption variables for all GBP+ and GBP− participants. A 
standard neurocognitive battery was administered, test specific 
Z-scores were calculated based on corresponding normative data, 
cognitive domains were formed from specific neurocognitive 
tasks as previously described, and summary scores were calcu-
lated for each cognitive domain and global cognition (34).
imaging and Processing Method
MRI data were acquired on a 4  T MedSpec system using an 
8-channel transmit-receive head coil and a Siemens Trio con-
sole (Siemens, Erlangen, Germany). A magnetization prepared 
rapid gradient (TR/TE/TI  =  2,300/3/950  ms, 7° flip angle, 
1 mm × 1 mm × 1 mm resolution) and a turbo spin-echo (TR/
TE = 8,400/70 ms, 150° flip angle, 0.9 mm × 0.9 mm × 3 mm reso-
lution) sequence were used to acquire 3-D sagittal T1-weighted 
and 2-D axial T2-weighted anatomical images, respectively. The 
images were then displayed on the scanner console for the pre-
scription of up to five different MRS volumes-of-interest (VOIs) 
acquired in two scanning sessions (for typical VOI locations see 
Figure 1). After VOI-specific 3-D shimming and optimization of 
water suppression, J-edited GABA spectra were acquired from 
the POC (size: 40  mm ×  20  mm ×  20  mm) using a modified 
MEGA PRESS sequence (TR/TE = 2,000/71, editing frequencies 
at 1.9 and 7.5 ppm, 12.5 min acquisition time) (35), followed by 
the acquisition of a water spectrum from the same VOI. This was 
then followed by the acquisition of a stimulated echo acquisi-
tion mode (STEAM) sequence (TR/TE/TM =  2,000/12/10  ms, 
2.5 min acquisition time) from the same VOI location. Additional 
STEAM metabolite and water spectra were acquired from 
the ACC (35  mm ×  25  mm ×  20  mm) and the right DLPFC 
(40 mm × 20 mm × 20 mm), with VOIs placed to maximize the 
inclusion of as much gray matter (GM) tissue as possible. For this 
FigUre 1 | Typical locations of MRS volumes-of-interest on  
transverse MRIs.
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analysis, GABA spectra from the ACC and DLPFC were available 
from all GBP− patients but only from two GBP+ patients, so that 
potential GABA differences in these VOIs could not be analyzed 
statistically.
In a second scan of all GBP+ patients generally within two days 
of the first scan, we further acquired metabolite and water STEAM 
spectra from the right basal ganglia (40 mm × 25 mm × 20 mm, 
including the head of the caudate, lenticular nucleus, and anterior 
thalamus) and the left frontal WM (25 mm × 15 mm × 20 mm), 
placed to include as much frontal WM tissue as possible (see 
Figure 1). Metabolite concentrations from these two subcortical 
VOIs were compared to the corresponding spectra available from 
a representative subgroup of 15 GBP− patients with characteris-
tics like those of the entire GBP− group; these subcortical spectra 
had been obtained in the previous year on the same scanner, 
with the same software version and with identical experimental 
parameters. The five brain VOIs were chosen because of our 
group’s longstanding interest in regional metabolite concentra-
tion changes during abstinence from alcohol [for review see 
Meyerhoff (13)].
All metabolite and water MRS data were processed using 
established routines of a combination of in-house Matlab pro-
grams and IDL (Research Systems, Inc., Boulder, CO, USA) 
with SITOOLS (14, 36), yielding peak areas for total NAA, Glu, 
total Cr, total Cho, mI, and water for all five VOIs and additional 
GABA signal from cortical VOIs. At 4 T magnetic field strength, 
the Glu signal can be measured separately from the glutamine 
signal, and in our implementation of the GABA editing method, 
the measured GABA signal has some contribution from co-edited 
macromolecules. The T1 images obtained at the time of MRS were 
segmented into GM, WM, and cerebrospinal fluid (CSF) (37) and 
yielded estimates of the tissue fraction and CSF contributions to 
each VOI; these measures did not differ between GBP− and GBP+ 
for any of the analyzed VOIs. The individual spectral and segmen-
tation information was then merged to calculate absolute molar 
concentrations [in institutional units (i.u.), i.e., without making 
assumptions about metabolite relaxation times] for metabolites 
in all VOIs, with details of these procedures described earlier (14).
Data analyses and statistics
Demographic and clinical variables were compared between 
GBP+ and GBP− groups with t-tests and Fisher’s exact test, 
where indicated. We previously reported extensively on metabo-
lite group differences between ALC (here called GBP−) and 
CON (14–16); consistent with those reports, in this new cohort, 
both NAA (p < 0.04) and Cr (p < 0.09) were lower in all three 
cortical VOIs of the entire ALC cohort of this report vs. CON. In 
this report, we focus on simple pairwise comparisons of region-
specific metabolite levels between GBP+ and GBP−. Any such 
significant differences were then further explored by pairwise 
comparisons to CON. Because of our specific a priori hypotheses 
for group comparisons (cortical GABA elevated, Glu unchanged), 
an uncorrected p < 0.05 was considered statistically significant. 
In exploratory analyses, Pearson correlations were calculated 
for associations of behavioral and GBP dose data with spectral 
outcome measures and corresponding partial correlations were 
computed where indicated.
resUlTs
group characteristics and gBP Dose
The GBP+ group was not significantly different from the GBP− 
group on sex distribution, average age, predicted premorbid 
intelligence, depressive and anxiety symptoms, self-reported 
impulsivity, common measures of lifetime alcohol consumption, 
and duration of abstinence from alcohol at the time of MR scan. 
The groups also did not differ significantly on cognitive domain 
summary scores (executive function, cognitive efficiency, process-
ing speed, working memory, audioverbal learning and memory, 
visuospatial learning and memory, visuospatial skills, fine motor 
skills; all p > 0.29) or global cognition (see Table 1). The propor-
tion of cigarette smokers was approximately equal between the 
GBP− (68%) and GBP+ groups (54%) and cigarette pack years 
as well as duration of lifetime smoking did not differ between the 
groups (all p > 0.25). However, the GBP+ had a lower Fagerstrom 
score than the GBP− group (p = 0.05), indicating low vs. moder-
ate nicotine dependence, respectively.
At the time of the MR scan, GBP+ patients had received at least 
1 week of oral GBP in three divided doses each day at a median 
daily dose of 1,200 mg (range: 800–3,600 mg, with 85% receiving 
between 800 and 1,800 mg; mean ± SD: 1,600 ± 900 mg). The 
large range of doses reflects different practices across treatment 
centers, different individual tolerance to the medication, and 
generally missing guidelines for the pharmacological treatment 
of alcohol dependence during early abstinence.
cortical Metabolite Measures
We compared cortical data from 13 GBP+ and 25 GBP− patients 
(unless otherwise specified). In the POC, none of the measured 
absolute metabolite concentrations (GABA, Glu, NAA, Cr, Cho, 
and mI) differed between GBP+ and GBP− (all p > 0.30). In the 
ACC, Glu, NAA, Cr, and Cho were equivalent between GBP+ 
and GBP− (all p > 0.20), while mI tended to be lower in GBP+ 
(p =  0.08). In the DLPFC, Glu, NAA, Cr, Cho, and mI were 
not different between GBP+ and GBP− (all p >  0.32). GABA 
FigUre 2 | Measured glutamate (Glu) concentrations [institutional units (i.u.)] by volume-of-interest and group. Mean ± SE. Only the differences in frontal white 
matter (fro WM) Glu of GBP− to GBP+ (p = 0.017) and controls (CON) (p = 0.026) reached statistical significance.
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concentrations from the ACC and DLPFC were only obtained 
in two GBP+ participants each and their values were within the 
range of the values obtained in the 25 GBP− patients.
subcortical Metabolite Measures
In the basal ganglia, similar to our findings in the ACC, the Glu, 
NAA, Cr, and Cho concentrations did not differ between 13 
GBP+ and 15 GBP− patients (all p > 0.30), while mI tended to 
be lower in GBP+ (p = 0.08).
In the frontal WM, Glu was 15% lower in the 13 GBP+ vs. 15 
GBP− patients (2.23 ± 0.39 vs. 2.61 ± 0.36, p = 0.017; Cohen’s 
d effect size = 0.99), while NAA, Cr, Cho, and mI were statisti-
cally equivalent between the groups (all p >  0.12). The lower 
frontal WM Glu in GBP+ remained significant after covarying 
for Fagerstrom total score, indicating that the Glu difference 
was independent of the severity of nicotine dependence. The 
lower frontal WM Glu of the GBP+ group showed a moderately 
strong, but non-significant correlation, with higher daily GBP 
dose (univariate r = −0.47, p = 0.12; partial r = −0.58, p = 0.13, 
with abstinence duration as covariate); by contrast, none of the 
cortical GABA and Glu concentrations correlated even weakly 
with GBP dose. The frontal WM Glu in GBP+ was not associ-
ated with any measure of lifetime alcohol consumption, smoking 
severity, or age.
In group comparisons of basal ganglia and frontal WM 
metabolite levels available from a subset of 10 of the 16 CON 
participants, frontal WM Glu was significantly higher in GBP− 
vs. CON (2.61 ± 0.36 vs. 2.20 ± 0.46, p = 0.026), whereas it was 
statistically equivalent between GBP+ and CON (2.23 ± 0.39 vs. 
2.20 ± 0.46, p = 0.85). The combined group of ALC participants 
showed no such Glu difference compared to the subset of CON 
(p  >  0.18). Furthermore, the GBP+ and GBP− groups did 
not differ from CON on any of the other regional metabolite 
concentrations.
All findings remained essentially the same when re-analyzing 
the data without the small number of women included in this U.S. 
Veterans sample. Figure 2 is a bar graph of Glu concentrations 
(i.u.) observed in the different VOIs across CON, GBP−, and 
GBP+ groups.
associations of Frontal WM glu With 
neuropsychological Measures
Within the ALC group (GBP+ and GBP− combined), all correla-
tions of frontal WM Glu with the summary scores for cognitive 
domains and global cognition were positive (all r = 0.044–0.525), 
indicating that higher frontal WM Glu was associated with bet-
ter cognitive function. This relationship was observed for both 
groups; also, recall that the GBP groups did not differ significantly 
on cognitive performance. The strongest and most significant 
correlations were observed with visuospatial memory (r = 0.525, 
p = 0.004) and visuospatial learning (r = 0.456, p = 0.015), while 
the corresponding correlations with cognitive efficiency and 
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global cognition were at the trend level (r > 0.380, p < 0.075). 
None of the associations of frontal WM Glu with measures of 
self-reported impulsivity and anxiety was significant.
DiscUssiOn
We tested whether ALC in early recovery treated daily with oral 
GBP for at least 1 week had higher cortical GABA and altered 
tissue-specific Glu concentrations compared to demographically 
and clinically similar ALC not treated with GBP. Counter to the 
general notion and our hypothesis that GBP administration would 
elevate brain GABA levels, GABA concentration in the POC did 
not statistically differ between GBP− and GBP+ groups. In addi-
tion, Glu levels in POC and in our frontal cortical (ACC, DLPFC) 
and basal ganglia VOIs did not differ between the groups. As such, 
GBP treatment at a median dose of 1,200 mg/day for at least 1 week 
was not associated with altered cortical GABA or cortical and 
basal ganglia Glu levels in short-term abstinent ALC. However, 
ALC receiving GBP had markedly lower Glu in the frontal WM 
than matched ALC not receiving GBP, and this Glu reduction 
showed a moderately strong but not significant relationship 
with a higher estimated daily GBP dose. Furthermore, whereas 
the frontal WM Glu concentration was significantly elevated in 
GBP− relative to CON, it was normal in GBP+. Although we did 
not gather serial withdrawal- or craving-related data, behavioral 
or reliable subsequent relapse data, we tentatively conclude that 
GBP for the treatment of alcohol dependence and/or associated 
craving, insomnia, anxiety, or mood does not work primarily 
through increasing cortical GABA levels. Rather, chronic GBP 
treatment may work through reducing metabolic Glu in WM as 
previously suggested in general (3, 5, 6) and specifically for the 
treatment of alcohol withdrawal (3).
Notably, chronic GBP treatment in recovering ALC was not 
associated with elevated MRS-observable central GABA levels. 
Equivalent GABA levels in those treated and not treated with 
GBP and their normal levels compared to healthy controls [Ref. 
(14–16) and this study] contrast with conditions in epilepsy, 
where daily GBP treatment increases initially low GABA levels 
and reduces seizure activity (10, 12, 38). In further contrast to 
epilepsy studies, we also did not find a dependence of cortical 
GABA levels during treatment on GBP dose. Since we studied our 
patients 2–3 weeks after their last alcoholic drink when all poten-
tial acute withdrawal symptoms had subsided (CIWA-Ar score 
below 10), it is possible that potentially low GABA levels during 
acute withdrawal (and potentially higher CIWA-Ar scores) had 
already normalized in these patients. In that phase, continued 
treatment with GBP may not further increase brain GABA levels. 
This explanation is reminiscent of studies performed in epilepsy 
patients, who showed a blunted GABA increase with daily GBP 
treatment after initially low GABA levels had normalized (12).
Also, cortical and basal ganglia Glu levels in our recovering 
ALC were not associated with chronic daily GBP treatment, 
consistent with the absence of occipital cortical Glu changes after 
oral GBP challenge in healthy controls (8, 9). To further explore 
GBP’s potential brain tissue-type specific metabolic sequelae, we 
also compared 1H MRS metabolic information from a prefrontal 
VOI that contained primarily WM in ALC receiving and not 
receiving daily GBP and found significantly lower frontal WM 
Glu in GBP+. The observed WM Glu level in our human studies 
was reduced as a function of the administered daily GBP dose, 
but not as a function of prior alcohol consumption. These tissue-
specific Glu alterations suggest that daily GBP adminis tration 
in early abstinence affects primarily and specifically cells in the 
WM and that those metabolic alterations may reflect the potential 
mechanisms of action of GBP, as previously suggested (3). Of 
note, GBP treatment normalized frontal WM Glu levels (i.e., it 
did not reduce frontal WM Glu below levels measured in CON). 
This may be clinically important, given that lower Glu in frontal 
WM was found associated with loss of control of alcohol use and 
severity of alcohol dependence (39).
These results of our human study are somewhat consistent 
with an ex vivo mouse study, in which chronic treatment with 
GBP at doses commensurate with those used in our patients did 
not affect global brain GABA levels but did reduce global Glu 
levels (40). The authors concluded that the clinical activity of 
GBP is not likely related to metabolic GABA or Glu levels, but 
potentially to neurotransmitter GABA levels that may have only 
increased in discrete brain regions.
Our study is distinctive in the number of brain regions inves-
tigated spectroscopically in any alcohol-dependent cohort and 
in addressing the question of potential metabolic effects of daily 
oral GBP in recovering ALC. Whereas the findings contribute to 
our understanding of GBP’s potential neurobiological mechanism 
of action, they also have limitations: one, the cohort constituted 
a modestly sized convenience sample of treatment-seeking 
individuals with AUDs. Two, while both men and women were 
studied (with comparable proportions across the groups), the 
women were not studied at the same phase of their menstrual 
cycle. As GABA levels vary as a function of the menstrual phase 
(41), corresponding noise in the data may have reduced our 
ability to detect GABA group differences. However, our find-
ings remained essentially the same when re-analyzing the data 
without the women included. Three, our study was observational 
and participants were not randomly assigned to the two study 
groups; furthermore, due to different abilities to endure long scan 
times, not all participants contributed spectral data from all five 
VOIs. Therefore, salient differences may exist between the groups 
analyzed that we had not considered. This limitation is somewhat 
mitigated, however, by our main comparison groups not differ-
ing on many potentially confounding clinical, demographic, and 
behavioral variables. Nevertheless, it is still possible that daily GBP 
treatment affects selectively discrete and functionally relevant 
neurotransmitter pools of GABA, which cannot be separately 
observed by our method. Finally, we report on cross-sectional 
comparisons between carefully matched samples studied after 
acute withdrawal; only serial MRS bracketing the acute withdrawal 
phase with data obtained before and after a prospective and well-
controlled daily GBP administration protocol will definitively link 
causation to symptom and metabolite level changes.
In summary, in treatment-seeking ALC at 2–3  weeks of 
abstinence, daily administration of GBP at an average dose of 
1,600 mg/day for at least 1 week before study was not associated 
with altered 1H MRS-observable cortical GABA, Glu, or other 
metabolite levels. As such, in MRS studies of cortical metabolite 
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concentrations during abstinence from alcohol, patients on this 
GBP regimen (or on lower doses) can be pooled for data analyses 
with patients not on GBP. However, daily GBP treatment was 
associated with uniquely lower frontal Glu in a predominantly 
WM VOI, to the degree that Glu levels were equivalent to those 
in non/light-drinking healthy controls. Rather than pointing to 
GBP’s ability to increase the metabolic pool of cortical GABA dur-
ing early abstinence from alcohol (via promoting GABA synthesis 
and/or boosting GABA levels), the observed metabolic effects may 
point to primary WM involvement—glial and/or axonal—in the 
mechanism of action of GBP during early abstinence, potentially 
via activating glutamate dehydrogenase (42). Thus, in regard to 
examining WM metabolite levels during abstinence from alcohol, 
patient groups on and off GBP should be analyzed separately.
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